Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
Amber R. Cothran
Advertisement
Amber R. Cothran is an engineer in late-stage purification at Genentech, Inc.
Articles by Amber R. Cothran
Advertisement
Latest Updated Articles
Purification Strategies to Process 5 g/L Titers of Monoclonal AntibodiesPublished: March 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
How Enzymatic Platforms May Change the Therapeutic RNA Supply Chain
2
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
3
BioPharma By the Numbers: Bioprocess Hiring Creating Capacity Constraints
4
Q&A: Strategies for Supply Chain Resilience and Next-Generation Process Optimization
5
